SOPHiA GENETICS Closes $57.5M Public Offering with Full Underwriter Option Exercise
Summary
SOPHiA GENETICS has completed its public offering, raising $57.5 million by selling 12.1 million ordinary shares at $4.75 each, including the full exercise of the underwriters' option.
Key Events
-
Public Offering Closed
SOPHiA GENETICS closed its underwritten public offering, selling a total of 12,104,900 ordinary shares.
-
Gross Proceeds
The offering generated gross proceeds of approximately $57.5 million before deducting underwriting discounts and expenses.
-
Pricing and Dilution
Shares were sold at $4.75 per share, a discount to the current market price, resulting in significant dilution for existing shareholders.
-
Underwriters' Option Fully Exercised
The underwriters fully exercised their option to purchase an additional 1,578,900 ordinary shares, indicating strong demand for the offering.
Analysis
This 6-K finalizes the terms of the underwritten public offering, confirming the sale of 12.1 million ordinary shares for gross proceeds of $57.5 million. The offering was priced at $4.75 per share, a discount to the current market price of $5.47, and included the full exercise of the underwriters' option to purchase additional shares. This significant capital raise, representing approximately 14.7% of the company's market capitalization and about 17% dilution to existing shares, provides substantial funding but also results in considerable dilution for existing shareholders. This filing follows the preliminary prospectus supplement filed on June 16, 2026, and the pricing announcement on June 17, 2026, with news reporting the closing on June 19, 2026.
At the time of this filing, SOPH was trading at $5.47 on NASDAQ in the Technology sector, with a market capitalization of approximately $391.3M. The 52-week trading range was $2.59 to $5.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.